Second phase 3 study of CaPre in patients with severe hypertriglyceridemia
Phase of Trial: Phase III
Latest Information Update: 13 Nov 2017
At a glance
- Drugs Omega-3 phospholipid (Primary)
- Indications Hypertriglyceridaemia
- Focus Registrational; Therapeutic Use
- Sponsors Acasti Pharma
- 13 Nov 2017 According to an Acasti Pharma media release, phase 3 program is anticipated to complete in 2019.
- 07 Nov 2017 According to an Acasti Pharma media release, Dariush Mozaffarian will be principal investigator of the phase 3 program. Acasti remains on track to begin activating sites for its Phase 3 program before the end of the year, with patient dosing expected to start in early 2018.
- 06 Jun 2017 According to an Acasti Pharma media release, the company plans to initiate this study in the second half of 2017.